FeesSafety
Pluang+

Purple Biotech reports Q3 2026 results, advances cancer drug IM1240 toward human trials with new patent granted

Company Fundamentals
17 Nov 2026, 14:55 WIB
GlobeNewsWire
View Source
Bullish
Purple Biotech reports Q3 2026 results, advances cancer drug IM1240 toward human trials with new patent granted

Purple Biotech announced its financial results for Q3 2026, showing reduced operating losses and ongoing R&D progress. The company is preparing an Investigational New Drug (IND) application for its lead cancer immunotherapy candidate IM1240, targeting a first-in-human study in 2027. IM1240 data will be presented at a major oncology symposium, highlighting its novel tri-specific antibody platform designed to engage T cells and NK cells to fight tumors with minimized toxicity. Additionally, Purple Biotech secured a U.S. patent for its CAPTN-3 platform, strengthening its intellectual property and development prospects. The company reported a cash runway through late 2027, supporting continued clinical development and AI-driven antibody design efforts.

Purple Biotech's Q3 2026 financial results and business update provide context for health sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 17, 2026 18:51 WIB: out of 150 priced health-sector US stocks, 51 rose and 91 fell. Notable movers include INO at USD 1.43 with a 1-day change of +2.14% and a Pluang order activity of 89% Sell / 11% Buy, DYN at USD 16.35 down 2.10%, and GH at USD 146.98 up 2.05%.

More News

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene Inc. and City of Hope have started a Phase 1 clinical trial testing a new combination therapy for metastatic colorectal cancer patients resistant to standard treatments. The trial evaluates two experimental drugs, ivonescimab and muzastotug (...

Others
Bullish
58 minutes ago
Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank announced three key leadership appointments to strengthen its Commercial Banking division. Edward Galan will lead Middle Market Lending, Dawn Scocco will manage portfolio and credit risk, and John Maio will head Treasury Management Ser...

Market News
Bullish
58 minutes ago
RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand Company Ltd. has released its first mobile game, Palazzo Chronicles: Match 3, on the Google Play Store. The free-to-play match-3 puzzle game features over 270 levels where players restore a royal palace set in Risorgimento Italy. This launch...

Others
Bullish
58 minutes ago
Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan, with over 25 years in financial technology including roles at Goldman Sachs and Coinbase, has joined Dune as Director of Engineering. He will lead the engineering efforts behind Dune Market Data Feeds, which provide real-time trade and liq...

Others
Bullish
58 minutes ago
BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock, Inc. has increased its total voting rights in ICG PLC to 5.16% as of November 13, 2026, up from 5.17% previously reported. This includes 5.08% voting rights attached to shares and 0.08% through financial instruments. The notification was o...

Market News
Neutral
58 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App